2.4.0.8158 - Disclosure - Changes in Investment of Kanghong Sagent Pharmaceutical Corporation Limited (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE715633--1310-Q0007_STD_91_20130630_0http://www.sec.gov/CIK0001369786duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE715633--1310-Q0007_STD_91_20120630_0http://www.sec.gov/CIK0001369786duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE715633--1310-Q0007_STD_181_20130630_0http://www.sec.gov/CIK0001369786duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE715633--1310-Q0007_STD_182_20120630_0http://www.sec.gov/CIK0001369786duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ScheduleOfEquityMethodInvestmentsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Schedule of Equity Method Investments [Line Items]2false 4us-gaap_EquityMethodInvestmentsus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse1962200019622USD$falsetruefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33749-111570 false2Investment at beginning of year3false 4us-gaap_IncomeLossFromEquityMethodInvestmentsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse160000160USD$falsefalsefalse2truefalsefalse-105000-105USD$falsefalsefalse3truefalsefalse603000603USD$falsefalsefalse4truefalsefalse351000351USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33749-111570 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.12) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 11 -Article 7 false2Equity in net loss (income) of joint ventures4false 4us-gaap_EquityMethodInvestmentsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse20160002016USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse20160002016USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33749-111570 false2Investment at end of year5false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5false USDtruefalse$eol_PE715633--1310-Q0007_STD_181_20130630_0_714258x826738http://www.sec.gov/CIK0001369786duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseKSCPus-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisxbrldihttp://xbrl.org/2006/xbrldisgnt_KanghongSagentPharmaceuticalCorporationLimitedMemberus-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0KSCP6true 3us-gaap_ScheduleOfEquityMethodInvestmentsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Schedule of Equity Method Investments [Line Items]7false 4us-gaap_EquityMethodInvestmentsus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse1746100017461USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33749-111570 false2Investment at beginning of year8false 4us-gaap_IncomeLossFromEquityMethodInvestmentsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-1825000-1825USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33749-111570 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.12) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 11 -Article 7 false2Equity in net loss (income) of joint ventures9false 4us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse294000294USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669646-108580 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (b,c) -URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900 false2Currency translation adjustment10false 4us-gaap_PaymentsToAcquireEquityMethodInvestmentsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse1900019USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 false2Investments11false 4sgnt_EquityMethodInvestmentIncreaseDecreaseOtherThanEarningsDistributionsgnt_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-15949000-15949USD$falsetruefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryEliminating of carrying amount of equity investment when financial results are included in consolidated results after gaining controlling voting interest that was previously accounted for as an equity method investment.No definition available.false2Acquisition of remaining equity interest in KSCPfalseChanges in Investment of Kanghong Sagent Pharmaceutical Corporation Limited (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.sagentpharma.com/taxonomy/role/DisclosureChangesInInvestmentOfKanghongSagentPharmaceuticalCorporationLimited411